Improvement of glycemic control in patients with type 2 diabetes mellitus
Who takes it
Adults
Adult dose
The dose of this drug for antidiabetic therapy should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: linagliptin 5mg and metformin hydrochloride extended-release 2000 mg.
This drug should be taken once daily with a meal, preferably with the evening meal. To reduce gastrointestinal adverse reactions associated with metformin use, the dose of metformin hydrochloride should be increased gradually.
To maintain its extended-release properties, this drug must be swallowed whole and must not be split, crushed, ground, or chewed.
Take 1 tablet of this drug 5/1000 mg extended-release tablets once daily.
Patients taking this drug 2.5/1000 mg extended-release tablets should take 2 tablets at the same time once daily.
1. Patients not currently receiving metformin:
The initial dose of this drug is a total daily dose of linagliptin 5 mg and metformin hydrochloride 1000mg. The dose of metformin hydrochloride may be increased gradually up to the maximum recommended daily dose of 2000 mg.
2. Patients receiving metformin
- For patients who cannot achieve adequate glycemic control with metformin monotherapy, the initial dose of this drug is a total daily dose of linagliptin 5 mg and the patient's current dose of metformin hydrochloride.
- For patients who cannot achieve adequate glycemic control with combination therapy of metformin and a sulfonylurea or metformin and insulin, an initial dose of this drug consisting of a total daily dose of linagliptin 5mg and a dose of metformin hydrochloride similar to the patient's current dose should be considered. When this drug is administered in combination with insulin or a sulfonylurea, a reduction in the dose of insulin or the sulfonylurea may be necessary to reduce the risk of hypoglycemia.
- When switching from an immediate-release metformin formulation to an extended-release formulation, glycemic control should be closely monitored and the dose adjusted appropriately if necessary.
- When switching from combination therapy with linagliptin and extended-release metformin to this drug, the dose of this drug should correspond to the patient's current doses of linagliptin and extended-release metformin hydrochloride.
Renal impairment
Because dose adjustment is required according to renal function, assessment of renal function is recommended before and periodically after administration of this drug.
No dose adjustment of this drug is necessary in patients with mild renal impairment [creatinine clearance (CrCl) ≧ 60mL/min or estimated glomerular filtration rate (eGFR) ≧ 60mL/min/1.73 m2].
In patients with moderate renal impairment (CKD stage 3A), defined as creatinine clearance (CrCl) of 45mL/min or more and less than 60mL/min, or estimated glomerular filtration rate (eGFR) of 45mL/min/1.73m2 or more and less than 60mL/min/1.73m2, this drug may be used with adjustment of the metformin hydrochloride dose as follows, if it is well tolerated and the patient has no other conditions that may increase the risk of lactic acidosis.
The starting dose of metformin hydrochloride is 500mg or 750mg once daily; therefore, treatment should not be initiated with this drug. The maximum daily dose of metformin hydrochloride is 1000mg.
If creatinine clearance (CrCl) decreases to less than 45mL/min or estimated glomerular filtration rate (eGFR) decreases to less than 45mL/min/1.73m2, this drug must be discontinued immediately.
Improvement of glycemic control in patients with type 2 diabetes mellitus
View approved original textHide original text
This medication is prescribed to assist patients with type 2 diabetes in blood sugar control when linagliptin and metformin need to be used together. Taking this medication alongside dietary changes and exercise can significantly aid in blood sugar management. Therefore, it is used effectively for controlling blood sugar in type 2 diabetes treatment.
How to take
Adult dose
The dose of this drug for antidiabetic therapy should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: linagliptin 5mg and metformin hydrochloride extended-release 2000 mg.
This drug should be taken once daily with a meal, preferably with the evening meal. To reduce gastrointestinal adverse reactions associated with metformin use, the dose of metformin hydrochloride should be increased gradually.
To maintain its extended-release properties, this drug must be swallowed whole and must not be split, crushed, ground, or chewed.
Take 1 tablet of this drug 5/1000 mg extended-release tablets once daily.
Patients taking this drug 2.5/1000 mg extended-release tablets should take 2 tablets at the same time once daily.
1. Patients not currently receiving metformin:
The initial dose of this drug is a total daily dose of linagliptin 5 mg and metformin hydrochloride 1000mg. The dose of metformin hydrochloride may be increased gradually up to the maximum recommended daily dose of 2000 mg.
2. Patients receiving metformin
- For patients who cannot achieve adequate glycemic control with metformin monotherapy, the initial dose of this drug is a total daily dose of linagliptin 5 mg and the patient's current dose of metformin hydrochloride.
- For patients who cannot achieve adequate glycemic control with combination therapy of metformin and a sulfonylurea or metformin and insulin, an initial dose of this drug consisting of a total daily dose of linagliptin 5mg and a dose of metformin hydrochloride similar to the patient's current dose should be considered. When this drug is administered in combination with insulin or a sulfonylurea, a reduction in the dose of insulin or the sulfonylurea may be necessary to reduce the risk of hypoglycemia.
- When switching from an immediate-release metformin formulation to an extended-release formulation, glycemic control should be closely monitored and the dose adjusted appropriately if necessary.
- When switching from combination therapy with linagliptin and extended-release metformin to this drug, the dose of this drug should correspond to the patient's current doses of linagliptin and extended-release metformin hydrochloride.
Renal impairment
Because dose adjustment is required according to renal function, assessment of renal function is recommended before and periodically after administration of this drug.
No dose adjustment of this drug is necessary in patients with mild renal impairment [creatinine clearance (CrCl) ≧ 60mL/min or estimated glomerular filtration rate (eGFR) ≧ 60mL/min/1.73 m2].
In patients with moderate renal impairment (CKD stage 3A), defined as creatinine clearance (CrCl) of 45mL/min or more and less than 60mL/min, or estimated glomerular filtration rate (eGFR) of 45mL/min/1.73m2 or more and less than 60mL/min/1.73m2, this drug may be used with adjustment of the metformin hydrochloride dose as follows, if it is well tolerated and the patient has no other conditions that may increase the risk of lactic acidosis.
The starting dose of metformin hydrochloride is 500mg or 750mg once daily; therefore, treatment should not be initiated with this drug. The maximum daily dose of metformin hydrochloride is 1000mg.
If creatinine clearance (CrCl) decreases to less than 45mL/min or estimated glomerular filtration rate (eGFR) decreases to less than 45mL/min/1.73m2, this drug must be discontinued immediately.
Precautions
This medication helps to control blood sugar levels. However, it can rarely cause lactic acidosis, a dangerous condition due to the buildup of lactic acid in the body, so caution is required. It should not be used in individuals with allergies to this medication, type 1 diabetes, severe kidney dysfunction, liver dysfunction, acute infections, dehydration, or acute cardiac problems. Pregnant women or those with placental dysfunction should also avoid this medication. There is a risk of hypoglycemia when taking this medication, especially when used in combination with insulin or other antidiabetic agents, so blood sugar levels must be monitored closely. Patients with reduced kidney function should undergo regular kidney function tests, and this medication should not be used in cases of severe kidney impairment. Additionally, the medication should be temporarily discontinued before and after acute surgery or radiological examinations and can be resumed once kidney function has returned to normal. Rare side effects such as pancreatitis or skin blistering similar to pemphigus may occur, so if severe abdominal pain or skin abnormalities arise during treatment, the doctor should be informed immediately. Long-term use may lower vitamin B12 levels, so vitamin B12 testing should be done if symptoms of anemia or neurological abnormalities occur. This medication should be swallowed whole without breaking, chewing, or crushing. The outer shell of the tablet may appear in stool, which is normal. Additionally, this medication may interact with other drugs, so if other medications are being taken, it's essential to consult with a doctor or pharmacist. Elderly individuals are at higher risk of decreased kidney function, so appropriate dose adjustments and regular kidney function testing are necessary. Finally, overdosing on this medication may lead to serious side effects like lactic acidosis, so the prescribed dose must be strictly followed, and in case of overdose, immediate medical attention should be sought.
Side effects
Severe lactic acidosis
hypoglycemia
angioedema
urticaria
lactic acidosis
abnormal vitamin B12 absorption test
hypoglycemia
dysgeusia
cough
loss of appetite
Show 126 moreCollapse
diarrhea
constipation
nausea
pancreatitis
vomiting
abdominal pain
oral ulcers
abnormal liver function tests
hepatitis
pruritus
erythema
rash
bullous pemphigoid
arthralgia with severe and disability
rhabdomyolysis
increased lipase
increased amylase
nasopharyngitis
hypersensitivity reactions
constipation
upper abdominal pain
enterocolitis
intestinal obstruction
gastroenteritis
herpes zoster
cystitis
acute pyelonephritis
bronchitis
vestibular neuronitis
sepsis
pneumonia
decreased appetite
dehydration
hyperglycemia
cerebral infarction
stuttering
Alzheimer's-type dementia
chest pain
fever
facial edema
fatigue
chronic obstructive pulmonary disease
asthma
diabetic foot disease
skin lesions
liver metastasis
acute leukemia
basal cell carcinoma
non-small cell lung cancer
malignant pericardial effusion
stomach cancer
rectal cancer
pancreatic cancer
meniscus injury
pneumoconiosis
congestive heart failure
angina pectoris
acute myocardial infarction
unstable angina
cardiac arrest
diabetic retinopathy
acute kidney injury
end-stage renal disease
acute cholangitis
acute cholecystitis
cholangitis
dizziness
kidney transplant failure
pneumonia
hypertension
anxiety
insomnia
depression
contusion
bone contusion
concussion
bone fracture
hand fracture
confusional state
nocturia
dermatitis
hypertension
erectile dysfunction
goiter
vitreous hemorrhage
chest discomfort
weakness
pain
nosebleed
oropharyngeal pain
speech disorders
epistaxis
vocal cord polyp
dyslipidemia
hypercholesterolemia
osteoarthritis
limb pain
osteoporosis
arthropathy
musculoskeletal discomfort
myositis
myalgia
soft tissue mass
postmenopausal osteoporosis
rotator cuff syndrome
androgenetic alopecia
hyperhidrosis
hair loss
dermatitis
benign prostatic hyperplasia
dry eyes
cataracts
allergic conjunctivitis
dry eyes
cataracts
unstable angina
acute myocardial infarction
angina pectoris
unstable angina
cardiac arrest
palpitations
angina pectoris
acute myocardial infarction
unstable angina
unstable angina
cardiac arrest
Not everyone experiences these, and they can vary from person to person.
Storage
This medication should be stored in a tightly sealed container to prevent air or moisture from entering. It is important to maintain storage temperatures between 1 and 30 degrees Celsius to safely preserve the medication's effectiveness.
Appearance and packaging
Appearance
Oval sustained release tablet, white to almost white, engraved with LD21 on one side
Package unit
28 tablets/box (7 tablets/PTP x 4)
Same-ingredient medicines
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
Questions about this medicine
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety. Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.